Tuberc Respir Dis > Volume 85(4); 2022 > Article |
|
Authors’ Contributions
Conceptualization: Park JH, Jang HJ, Lee JH. Methodology: Park JH, Kim HK, Jang HJ. Formal analysis: Park JH, Choi HE, Kim IH. Data curation: Jang JH, Kim JY, Han JY, Kim DS, Kang E. Validation: Kim HK, Choi HE, Han JY, Kang MK. Investigation: Park JH, Kang MK, Han JY, Kim DS, Lee JH. Writing - original draft preparation: Park JH, Lee JH. Writing - review and editing: Park JH, Jang JH, Kim HK, Jang HJ, Lee S, Kim SH, Kim JY, Choi HE, Han JY, Kim DS, Kang MK, Kang E, Kim IH, Lee JH. Approval of final manuscript: all authors.
Values are presented as median (interquartile range) or number (%).
BAL: bronchalveola lavage; WBC: white blood cell; FVC: forced vital capacity; FEV1: forced expiratory volume in one second; DLco: diffusing capacity of the lungs for carbon monoxide; SpO2: saturation of percutaneous oxygen; ProBNP: prohormone of brain type ntriuretic peptide; LDH: lactate dehydrogenase; CRP: C-reactive protein; IL-6: interleukin-6.
Characteristic | Value |
---|---|
Hospital length of stay, day | 3.0 (3.0-4.0) |
Fogarty catheter | 2 (7.4) |
Univent endobronchial tube | 25 (92.6) |
7.0 Fr | 10 (40.0) |
7.5 Fr | 15 (60.0) |
Flexible bronchoscopy | 27 (100) |
Cryoprobe | |
1.7 mm (disposable) | 15 (55.6) |
1.9 mm (reusable) | 12 (44.4) |
Duration of procedure, min | 20.0 (15.0-30.0) |
Biopsy location | |
RLL | 17 (62.9) |
LLL | 10 (37.1) |
B8* | 33 (63.5) |
B9 | 18 (34.6) |
B6 | 1 (1.9) |
No. of specimens | 2.0 (2.0-2.0) |
Biopsy size, cm | |
Smallest axis diameter | 0.3 (0.2-0.3) |
Largest axis diameter | 0.5 (0.5-0.7) |
Bleeding | |
No bleeding | 10 (19.2) |
Mild bleeding | 19 (36.5) |
Moderate bleeding | 20 (38.5) |
Severe bleeding | 3 (5.8) |
Pneumothorax | 7 (25.9) |
Chest tube drain (+) | 2 (7.4) |
Chest tube drain (-) | 5 (18.5) |
Pneumonia | 0 (0) |
Acute exacerbation | 1 (3.7) |
Death | 0 (0) |
Characteristic | No. (%) |
---|---|
Radiologic pattern | |
UIP | 1 (3.7) |
Probable | 9 (33.3) |
Indeterminate UIP | 9 (33.3) |
Alternative UIP | 8 (29.7) |
Histopathologic pattern | |
UIP | 0 (0) |
Probable UIP | 5 (18.5) |
Indeterminate | 9 (33.3) |
Alternative | 13 (48.2) |
Specific alternative pattern | |
Smoking-related ILD | 6 (22.2) |
NSIP | 3 (11.1) |
Inhalation injury | 2 (7.4) |
PPFE | 1 (3.7) |
Lung cancer | 1 (7.7) |
Final MDD diagnosis | |
IPF | 9 (33.3) |
Smoking-related ILD* | 7 (25.9) |
NSIP | 5 (18.6) |
Unclassifiable ILD† | 4 (14.8) |
PPFE | 1 (3.7) |
Lung cancer | 1 (3.7) |
Treatment | |
Pirfenidone | 11 (40.7) |
Steroid | 11 (40.7) |
Immunosuppressive drug | 4 (14.8) |
No treatment | 5 (18.5) |
* Smoking-related ILD was defined as the distinct but heterogeneous group of parenchymal lung diseases which can be grouped into those that likely have a causal association with tobacco exposure [27].
Jin Han Park
https://orcid.org/0000-0002-1138-4957
Jae Ha Lee
https://orcid.org/0000-0003-0932-2826
Safety and Significance of Surgical Lung Biopsy for Interstitial Lung Disease.2007 July;63(1)